AACR 2023: Identification of DM004, A First-In-Class Anti-5T4/MET Bispecific Antibody-Drug Conjugate
Conclusions
DM004 BsADC candidates demonstrate robust anti-tumor efficacy in CDX and PDX models with different levels of 5T4 and MET expression, indicating DM004 has a strong potential for clinical benefit.
DM004’s parental 5T4 ADC shows excellent anti-tumor efficacy both in vitro and in vivo.
The reduced binding avidity of anti-MET monovalent antibodies suggests improved tumor selectivity for DM004 compared to anti-MET monoclonal antibody.
DM004 BsADC candidates demonstrate robust anti-tumor efficacy in CDX and PDX models with different levels of 5T4 and MET expression, indicating DM004 has a strong potential for clinical benefit.
+86-010-56967680
Copyright © 2024 Biocytogen. All Rights Reserved
Powered by Fractal-technology